ImmunoGen is a biotechnology company developing targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, coupled with its expertise in monoclonal antibodies and tumor biology. A TAP compound delivers one of ImmunoGen’s purpose-developed cancer-killing agents specifically to tumor cells using a tumor-targeting monoclonal antibody. Ten different TAP compounds are currently in clinical testing – three of which are wholly owned by ImmunoGen. For more information, visit the company’s Web site at www.immunogen.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: